

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A therapeutic method of modulating the immune response in a patient, which comprises administering to the patient an amount of IL-4 effective to promote peripheral blood lymphocyte adhesion to microvascular endothelial cells in lymphoid organs and thereby modulate the patient's immune response.
2. The method of Claim 1, wherein IL-18 is administered to the patient.
3. A therapeutic method for treating inflammation, which comprises administering to a patient needing treatment for inflammation an amount of IL-4 effective to promote transmigration of lymphocytes from blood across postcapillary venules at sites of inflammation in the patient.
4. The method of Claim 3, wherein IL-18 is administered to the patient.
5. In a method of screening a cell line for the production of a binding partner that binds with a cell adhesion molecule, including the steps of contacting the binding partner with cells bearing the cell adhesion molecule and detecting any binding reaction between the binding partner and the cells, the improvement comprising contacting the binding partner with IL4-activated and nonactivated microvascular endothelial cells and selecting cell lines that produce binding partners that bind to the IL4-activated microvascular endothelial cells but not to the nonactivated microvascular endothelial cells.
6. The improved method of Claim 5, comprising the additional screening step of thereafter testing the immunological binding partners of the selected cell lines for the ability to block lymphocyte binding to cytokine-activated endothelial cells.
7. A cell line selected by the method of Claim 5.
8. A binding partner produced by the cell line of Claim 7.
9. A cell line selected by the method of claim 6.

10. A binding partner produced by the cell line of Claim 9.
11. An immunological binding partner that specifically binds to IL4-activated but not nonactivated microvascular endothelial cells.
12. The immunological binding partner of Claim 11, further characterized by the ability to block lymphocyte binding to cytokine-activated endothelial cells.
13. The immunological binding partner of Claim 11, further characterized by binding with human VCAM-1.
14. The immunological binding partner of Claim 11, further characterized by binding to IL4-activated bone marrow stromal cells.
15. The immunological binding partner of Claim 13, further characterized by binding to IL4-activated bone marrow stromal cells.
16. The immunological binding partner of Claim 11, having the binding characteristics of mAb 6G10 produced by hybridoma ATCC No. _____.
17. A therapeutic method of modulating the immune response in a patient, which comprises administering to the patient an agent that specifically binds to IL4-activated microvascular endothelial cells, in an amount effective to impede transmigration of cells that specifically bind to VCAM-1 from blood across
5 postcapillary venules into extracellular fluid in the patient.
18. The method of Claim 17, wherein the agent is administered in an amount effective to impede transmigration of lymphocytes across postcapillary venules in the patient.

Sub B1

Add B2

add CO